NCT06459622

Brief Summary

The study will be conducted to identify factors predicting the response of chronic rhinosinusitis with nasal polyps ( CRSwNP) to oral corticosteroids.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
102

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2024

Shorter than P25 for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 31, 2024

Completed
3 months until next milestone

First Posted

Study publicly available on registry

June 14, 2024

Completed
17 days until next milestone

Study Start

First participant enrolled

July 1, 2024

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2025

Completed
Last Updated

June 14, 2024

Status Verified

March 1, 2024

Enrollment Period

8 months

First QC Date

March 31, 2024

Last Update Submit

June 10, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Serum IL-25 is measured to releave the relation between them and the response of CRSwNP to oral corticosteroids

    Serum IL-25 is related to the effect of corticosteroids on CRSwNP

    Baseline

Other Outcomes (1)

  • Eosinophils in nasal polyp tissue

    Baseline

Study Arms (2)

Sensitive to corticosteroids

EXPERIMENTAL

Patients who are sensitive to corticosteroids have high serum IL-25

Diagnostic Test: Serum IL_25 and eosinophils in nasal polyp tisuee

Non sensitive to corticosteroids

EXPERIMENTAL

Patients who aren't sensitive to corticosteroids have low serum IL-25

Diagnostic Test: Serum IL_25 and eosinophils in nasal polyp tisuee

Interventions

Serum IL-25 and eosinophils in nasal polyps tisuer obtained and measured to identify the sensitivity of nasal polyps to corticosteroids

Non sensitive to corticosteroidsSensitive to corticosteroids

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • clinical diagnosis of chronic rhinosinusitis with nasal polyps

You may not qualify if:

  • Patients who had taken any steroid , antihistamine or other immune-modulating medications within the past 4 weeks
  • previous nasal and sinus surgery.
  • Allergic Fungal rhinosinusitis.
  • Unilateral rhinosinusitis.
  • Antrochoanal polyps or cystic fibrosis.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Shin HW, Kim DK, Park MH, Eun KM, Lee M, So D, Kong IG, Mo JH, Yang MS, Jin HR, Park JW, Kim DW. IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2015 Jun;135(6):1476-85.e7. doi: 10.1016/j.jaci.2015.01.003. Epub 2015 Feb 25.

    PMID: 25725991BACKGROUND

Central Study Contacts

Katrina Atef, General practitioner

CONTACT

Alla Kamel, Professor

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Predictive factors in response of chronic rhinosinusitis with nasal polyps to corticosteroids

Study Record Dates

First Submitted

March 31, 2024

First Posted

June 14, 2024

Study Start

July 1, 2024

Primary Completion

March 1, 2025

Study Completion

May 1, 2025

Last Updated

June 14, 2024

Record last verified: 2024-03